Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis
Background Metastasis is the main cause of breast cancer (BC) mortality. Increasing evidence points to a role of syndecan-1 (CD138) expression as a prognostic marker involved in BC tissue and leptomeningeal metastasis. Aim of this study was to investigate and compare syndecan-1 tissue expression and...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental medicine 2023-09, Vol.23 (5), p.1641-1647 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1647 |
|---|---|
| container_issue | 5 |
| container_start_page | 1641 |
| container_title | Clinical and experimental medicine |
| container_volume | 23 |
| creator | Cerbelli, Bruna Pisano, Annalinda Pignataro, Maria Gemma Pernazza, Angelina Botticelli, Andrea Carosi, Mariantonia Costarelli, Leopoldo Allegretti, Matteo d’Amati, Giulia Cordone, Iole |
| description | Background
Metastasis is the main cause of breast cancer (BC) mortality. Increasing evidence points to a role of syndecan-1 (CD138) expression as a prognostic marker involved in BC tissue and leptomeningeal metastasis. Aim of this study was to investigate and compare syndecan-1 tissue expression and localization in primary and secondary BC, focusing on brain metastases.
Methods
Syndecan-1 expression was determined by immunohistochemistry. Focal
vs
diffuse ( 50% of cancer cells, respectively) pattern of expression, cellular localization (cytoplasm
vs
membrane) and intensity of immunostaining on neoplastic cells were evaluated. Moreover, the extent and pattern of expression of syndecan-1 were compared between primary tumors and paired metastases and correlated with the tumor intrinsic subtype.
Results
A total of 23 cases, 10 with paired primary and metastatic tumor and 13 brain metastases, were evaluated. Syndecan-1 was expressed in both primary and metastatic BC. A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process. Concerning the extent of expression, we observed in metastatic lesions, a trend of association between intrinsic subtypes and extent of positivity. In particular, both BC characterized by overexpression of HER2 and triple-negative tumors were correlated with a diffuse pattern of expression with a moderate to strong intensity.
Conclusion
A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process. |
| doi_str_mv | 10.1007/s10238-022-00880-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10460700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2857885169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-c5172e8e559329ab200a35cba2c995730f7ec583157a62575c32d50b4f65c7333</originalsourceid><addsrcrecordid>eNp9kU9vFDEMxSMEon_gC3CKxIXLFCfZTDKnClVAK1XqAThHmaxnSbuTTOOZVfvtSdkKWg6cbNm_92TrMfZOwIkAMB9JgFS2ASkbAGuhMS_YodCdaDot7csn_QE7IroGENoqeM0OVFt51clDNl7tsODdVJAo5sRj4iPOnmY_x8D7grXlwaeAhdMyTbnMxL_dpzXWYSO4J-756MtN3eehynee4g5TteM-rfmUc-FTyZuUKdIb9mrwW8K3j_WY_fjy-fvZeXN59fXi7NNlE1Zazk3Qwki0qHWnZOd7CeCVDr2Xoeu0UTAYDPUVoY1vpTY6KLnW0K-GVgejlDpmp3vfaelHXAdMc_FbN5VYT7132Uf3fJPiT7fJOydg1YIBqA4fHh1Kvl2QZjdGCrjd-oR5ISeNkFar1nYVff8Pep2Xkup_riLGWi3aB0ruqVAyUcHhzzUC3EOcbh-nq3G633E6U0VqL6IKpw2Wv9b_Uf0CaVKiXg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857885169</pqid></control><display><type>article</type><title>Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis</title><source>SpringerLink Journals - AutoHoldings</source><creator>Cerbelli, Bruna ; Pisano, Annalinda ; Pignataro, Maria Gemma ; Pernazza, Angelina ; Botticelli, Andrea ; Carosi, Mariantonia ; Costarelli, Leopoldo ; Allegretti, Matteo ; d’Amati, Giulia ; Cordone, Iole</creator><creatorcontrib>Cerbelli, Bruna ; Pisano, Annalinda ; Pignataro, Maria Gemma ; Pernazza, Angelina ; Botticelli, Andrea ; Carosi, Mariantonia ; Costarelli, Leopoldo ; Allegretti, Matteo ; d’Amati, Giulia ; Cordone, Iole</creatorcontrib><description>Background
Metastasis is the main cause of breast cancer (BC) mortality. Increasing evidence points to a role of syndecan-1 (CD138) expression as a prognostic marker involved in BC tissue and leptomeningeal metastasis. Aim of this study was to investigate and compare syndecan-1 tissue expression and localization in primary and secondary BC, focusing on brain metastases.
Methods
Syndecan-1 expression was determined by immunohistochemistry. Focal
vs
diffuse (< or > 50% of cancer cells, respectively) pattern of expression, cellular localization (cytoplasm
vs
membrane) and intensity of immunostaining on neoplastic cells were evaluated. Moreover, the extent and pattern of expression of syndecan-1 were compared between primary tumors and paired metastases and correlated with the tumor intrinsic subtype.
Results
A total of 23 cases, 10 with paired primary and metastatic tumor and 13 brain metastases, were evaluated. Syndecan-1 was expressed in both primary and metastatic BC. A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process. Concerning the extent of expression, we observed in metastatic lesions, a trend of association between intrinsic subtypes and extent of positivity. In particular, both BC characterized by overexpression of HER2 and triple-negative tumors were correlated with a diffuse pattern of expression with a moderate to strong intensity.
Conclusion
A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process.</description><identifier>ISSN: 1591-9528</identifier><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-022-00880-7</identifier><identifier>PMID: 36088392</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Brain cancer ; Brain tumors ; Breast cancer ; Cytoplasm ; ErbB-2 protein ; Hematology ; Immunohistochemistry ; Internal Medicine ; Invasiveness ; Lesions ; Localization ; Medicine ; Medicine & Public Health ; Meninges ; Metastases ; Metastasis ; Oncology ; Original ; Original Article ; Syndecan ; Tumors</subject><ispartof>Clinical and experimental medicine, 2023-09, Vol.23 (5), p.1641-1647</ispartof><rights>The Author(s) 2022</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-c5172e8e559329ab200a35cba2c995730f7ec583157a62575c32d50b4f65c7333</citedby><cites>FETCH-LOGICAL-c452t-c5172e8e559329ab200a35cba2c995730f7ec583157a62575c32d50b4f65c7333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10238-022-00880-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10238-022-00880-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Cerbelli, Bruna</creatorcontrib><creatorcontrib>Pisano, Annalinda</creatorcontrib><creatorcontrib>Pignataro, Maria Gemma</creatorcontrib><creatorcontrib>Pernazza, Angelina</creatorcontrib><creatorcontrib>Botticelli, Andrea</creatorcontrib><creatorcontrib>Carosi, Mariantonia</creatorcontrib><creatorcontrib>Costarelli, Leopoldo</creatorcontrib><creatorcontrib>Allegretti, Matteo</creatorcontrib><creatorcontrib>d’Amati, Giulia</creatorcontrib><creatorcontrib>Cordone, Iole</creatorcontrib><title>Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><description>Background
Metastasis is the main cause of breast cancer (BC) mortality. Increasing evidence points to a role of syndecan-1 (CD138) expression as a prognostic marker involved in BC tissue and leptomeningeal metastasis. Aim of this study was to investigate and compare syndecan-1 tissue expression and localization in primary and secondary BC, focusing on brain metastases.
Methods
Syndecan-1 expression was determined by immunohistochemistry. Focal
vs
diffuse (< or > 50% of cancer cells, respectively) pattern of expression, cellular localization (cytoplasm
vs
membrane) and intensity of immunostaining on neoplastic cells were evaluated. Moreover, the extent and pattern of expression of syndecan-1 were compared between primary tumors and paired metastases and correlated with the tumor intrinsic subtype.
Results
A total of 23 cases, 10 with paired primary and metastatic tumor and 13 brain metastases, were evaluated. Syndecan-1 was expressed in both primary and metastatic BC. A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process. Concerning the extent of expression, we observed in metastatic lesions, a trend of association between intrinsic subtypes and extent of positivity. In particular, both BC characterized by overexpression of HER2 and triple-negative tumors were correlated with a diffuse pattern of expression with a moderate to strong intensity.
Conclusion
A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process.</description><subject>Brain cancer</subject><subject>Brain tumors</subject><subject>Breast cancer</subject><subject>Cytoplasm</subject><subject>ErbB-2 protein</subject><subject>Hematology</subject><subject>Immunohistochemistry</subject><subject>Internal Medicine</subject><subject>Invasiveness</subject><subject>Lesions</subject><subject>Localization</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meninges</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Syndecan</subject><subject>Tumors</subject><issn>1591-9528</issn><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kU9vFDEMxSMEon_gC3CKxIXLFCfZTDKnClVAK1XqAThHmaxnSbuTTOOZVfvtSdkKWg6cbNm_92TrMfZOwIkAMB9JgFS2ASkbAGuhMS_YodCdaDot7csn_QE7IroGENoqeM0OVFt51clDNl7tsODdVJAo5sRj4iPOnmY_x8D7grXlwaeAhdMyTbnMxL_dpzXWYSO4J-756MtN3eehynee4g5TteM-rfmUc-FTyZuUKdIb9mrwW8K3j_WY_fjy-fvZeXN59fXi7NNlE1Zazk3Qwki0qHWnZOd7CeCVDr2Xoeu0UTAYDPUVoY1vpTY6KLnW0K-GVgejlDpmp3vfaelHXAdMc_FbN5VYT7132Uf3fJPiT7fJOydg1YIBqA4fHh1Kvl2QZjdGCrjd-oR5ISeNkFar1nYVff8Pep2Xkup_riLGWi3aB0ruqVAyUcHhzzUC3EOcbh-nq3G633E6U0VqL6IKpw2Wv9b_Uf0CaVKiXg</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Cerbelli, Bruna</creator><creator>Pisano, Annalinda</creator><creator>Pignataro, Maria Gemma</creator><creator>Pernazza, Angelina</creator><creator>Botticelli, Andrea</creator><creator>Carosi, Mariantonia</creator><creator>Costarelli, Leopoldo</creator><creator>Allegretti, Matteo</creator><creator>d’Amati, Giulia</creator><creator>Cordone, Iole</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230901</creationdate><title>Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis</title><author>Cerbelli, Bruna ; Pisano, Annalinda ; Pignataro, Maria Gemma ; Pernazza, Angelina ; Botticelli, Andrea ; Carosi, Mariantonia ; Costarelli, Leopoldo ; Allegretti, Matteo ; d’Amati, Giulia ; Cordone, Iole</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-c5172e8e559329ab200a35cba2c995730f7ec583157a62575c32d50b4f65c7333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Brain cancer</topic><topic>Brain tumors</topic><topic>Breast cancer</topic><topic>Cytoplasm</topic><topic>ErbB-2 protein</topic><topic>Hematology</topic><topic>Immunohistochemistry</topic><topic>Internal Medicine</topic><topic>Invasiveness</topic><topic>Lesions</topic><topic>Localization</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meninges</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Syndecan</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cerbelli, Bruna</creatorcontrib><creatorcontrib>Pisano, Annalinda</creatorcontrib><creatorcontrib>Pignataro, Maria Gemma</creatorcontrib><creatorcontrib>Pernazza, Angelina</creatorcontrib><creatorcontrib>Botticelli, Andrea</creatorcontrib><creatorcontrib>Carosi, Mariantonia</creatorcontrib><creatorcontrib>Costarelli, Leopoldo</creatorcontrib><creatorcontrib>Allegretti, Matteo</creatorcontrib><creatorcontrib>d’Amati, Giulia</creatorcontrib><creatorcontrib>Cordone, Iole</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cerbelli, Bruna</au><au>Pisano, Annalinda</au><au>Pignataro, Maria Gemma</au><au>Pernazza, Angelina</au><au>Botticelli, Andrea</au><au>Carosi, Mariantonia</au><au>Costarelli, Leopoldo</au><au>Allegretti, Matteo</au><au>d’Amati, Giulia</au><au>Cordone, Iole</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis</atitle><jtitle>Clinical and experimental medicine</jtitle><stitle>Clin Exp Med</stitle><date>2023-09-01</date><risdate>2023</risdate><volume>23</volume><issue>5</issue><spage>1641</spage><epage>1647</epage><pages>1641-1647</pages><issn>1591-9528</issn><issn>1591-8890</issn><eissn>1591-9528</eissn><abstract>Background
Metastasis is the main cause of breast cancer (BC) mortality. Increasing evidence points to a role of syndecan-1 (CD138) expression as a prognostic marker involved in BC tissue and leptomeningeal metastasis. Aim of this study was to investigate and compare syndecan-1 tissue expression and localization in primary and secondary BC, focusing on brain metastases.
Methods
Syndecan-1 expression was determined by immunohistochemistry. Focal
vs
diffuse (< or > 50% of cancer cells, respectively) pattern of expression, cellular localization (cytoplasm
vs
membrane) and intensity of immunostaining on neoplastic cells were evaluated. Moreover, the extent and pattern of expression of syndecan-1 were compared between primary tumors and paired metastases and correlated with the tumor intrinsic subtype.
Results
A total of 23 cases, 10 with paired primary and metastatic tumor and 13 brain metastases, were evaluated. Syndecan-1 was expressed in both primary and metastatic BC. A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process. Concerning the extent of expression, we observed in metastatic lesions, a trend of association between intrinsic subtypes and extent of positivity. In particular, both BC characterized by overexpression of HER2 and triple-negative tumors were correlated with a diffuse pattern of expression with a moderate to strong intensity.
Conclusion
A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36088392</pmid><doi>10.1007/s10238-022-00880-7</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1591-9528 |
| ispartof | Clinical and experimental medicine, 2023-09, Vol.23 (5), p.1641-1647 |
| issn | 1591-9528 1591-8890 1591-9528 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10460700 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Brain cancer Brain tumors Breast cancer Cytoplasm ErbB-2 protein Hematology Immunohistochemistry Internal Medicine Invasiveness Lesions Localization Medicine Medicine & Public Health Meninges Metastases Metastasis Oncology Original Original Article Syndecan Tumors |
| title | Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T20%3A01%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20in%20metastatic%20breast%20cancer%20supports%20Syndecan-1%20as%20a%20marker%20of%20invasiveness%20and%20poor%20prognosis&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Cerbelli,%20Bruna&rft.date=2023-09-01&rft.volume=23&rft.issue=5&rft.spage=1641&rft.epage=1647&rft.pages=1641-1647&rft.issn=1591-9528&rft.eissn=1591-9528&rft_id=info:doi/10.1007/s10238-022-00880-7&rft_dat=%3Cproquest_pubme%3E2857885169%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2857885169&rft_id=info:pmid/36088392&rfr_iscdi=true |